CJC-1295 vs MOTS-c
Side-by-Side Comparison
| Attribute | Cjc 1295 | Mots C |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Mitochondrial |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid... |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 5–10 mg SC per injection |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily or 3–5x weekly |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~2174.6 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Several hours; tissue effects may persist longer |
Overview
CJC-1295 and MOTS-c are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
MOTS-c is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
MOTS-c Guide: Mitochondrial Peptide for Canada Research
MOTS-c stands out as a 16-amino-acid peptide encoded by mitochondrial DNA, distinct from nuclear-gene peptides. Discovered in 2015, it influences metabolic regulation, AMPK signaling, and aging mechanisms. This guide details its features, verification steps, and research applications for Canadian buyers.
MOTS-c: The Mitochondrial Peptide for Metabolic Health
MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA, regulates metabolism and responds to stress by signaling from mitochondria to the nucleus. Research shows it activates AMPK, declines with age, and mimics exercise effects in preclinical models. Studies link lower levels to type 2 diabetes and age-related physical decline.